Impact of treatment suspension on health-related quality of life in the EMBARK trial: a post hoc analysis
Bibliographic record
Abstract
Background: Enzalutamide was approved for high-risk biochemically recurrent (hrBCR) prostate cancer based on the EMBARK trial (NCT02319837; 17 December 2014-31 January 2023). In EMBARK, treatment was suspended at week 37 if prostate-specific antigen (PSA) was <0.2 ng/mL and reinstated if PSA rose to ≥2.0 ng/mL with radical prostatectomy or ≥5.0 ng/mL without. This post hoc analysis assessed the impact of treatment suspension on health-related quality of life (HRQoL) to address overtreatment concerns. Methods: Longitudinal change in HRQoL from treatment suspension at week 37 to subsequent assessments until week 109 was analyzed with mixed models for repeated measures (MMRM) and descriptively among these patients. Separate models were used to assess four patient-reported outcome (PRO) instruments-Brief Pain Inventory - short form, Functional Assessment of Cancer Therapy - Prostate, QoL Questionnaire - Prostate 25, and European QoL 5-Dimensions 5-Levels health questionnaire-with predefined clinically meaningful thresholds. Intention-to-treat analysis was used. Findings: Treatment was suspended in 90% (321/355), 86% (304/355), and 67% (240/358) of participants treated with enzalutamide + leuprolide, enzalutamide monotherapy, and leuprolide alone, respectively. MMRM showed no meaningful change in any treatment arm after treatment suspension across all assessed PRO measures, except hormonal treatment-related symptoms, for which clinically meaningful improvement was observed after treatment suspension at week 61 for enzalutamide monotherapy, week 73 for leuprolide alone, and week 85 for enzalutamide + leuprolide. The descriptive analysis showed similar findings. Interpretation: Enzalutamide ± leuprolide in patients with hrBCR improves metastasis-free survival versus leuprolide alone with no clinically meaningful changes in the measured HRQoL domains during treatment or after treatment suspension, with gradual improvement in hormonal treatment-related symptoms after treatment suspension in this selective clinical trial population. Further real-world studies are warranted to better explore the benefits of treatment suspension. Funding: This study was funded by Pfizer Inc. and Astellas Pharma Inc.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".